StrokeNCT02077023
An Observational Study of Natural History of Cardiovascular Diseases
An observational study of Stroke and Heart Attack, run by Imperial College London at 1 site in United Kingdom.
Trial summary
The purpose of the study is to estimate the contemporary prevalence of cardiovascular diseases in the United Kingdom (UK) and to describe the incidence and prevalence of stroke, mini stroke (TIA), Heart Attack (MI), deaths and interventions repairs for carotids and occlusive arterial disease in a large population. Read more about this study
- Who is it for?
- Ages 20 years and olderHealthy volunteers can take part
- Conditions the study is for
- Stroke, Heart Attack, TIA
- How many people
- 456 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Feb 2014to May 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 20 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: The study consists of an observational, prospective study of the prevalence of and risk factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended cardiovascular screening appointments provided by Life Line Screening. This cohort will include 1300 participants who are exposed to significant carotid artery stenosis (more than 50% artery occlusion identified by ultrasound scan) and atrial fibrillation. We also aim to recruit 3900 participants who do not have carotid artery disease or atrial fibrillation as control group and for comparison purposes. The control group will be drawn from a population that is similar to the exposed group in all respects other than their carotid disease and atrial fibrillation. The data collected for the control group will be the same and will be obtained in the same way as those on the exposed group.
Who may be able to join
- Participants who underwent self-selected, private screening program held by Life Line Screening
- Adult participants over the age of 20
- Participants who filled in appropriate health questionnaire and signed relevant consent part of their questionnaire
- Cohort observation cases: participants with significant carotid artery disease (>50% stenosis) detected by duplex ultrasound and/or AF
- Cohort observation controls: Participants without CAS detected by Duplex ultrasound or AF
Who cannot join
- Those who are unable to give informed consent
- Participants under 20 years old
- Participants who filled in the health questionnaire incompletely
Trial locations and contacts
1 site in 1 country.
About this study
The purpose of the study is to estimate the contemporary prevalence of cardiovascular diseases in the United Kingdom (UK) and to describe the incidence and prevalence of stroke, mini stroke (TIA), Heart Attack (MI), deaths and interventions repairs for carotids and occlusive arterial disease in a large population. This study will also allow us to obtain reliable information on the age- and sex-specific relevance of tobacco and alcohol consumption, obesity, diabetes and blood pressure as risk factors for different cardiovascular diseases. By following up a large group of participants for 5 years, we will be able to estimate the annual risk of stroke and other CVD events associated with asymptomatic carotid artery stenosis and atrial fibrillation.
Read the detailed description
Cardiovascular disease (CVD) affects the lives of millions of people and is one of the largest causes of death and disability in this country. Huge improvements have been made in the prevention and treatment of CVD over the last decade. However, comparisons with other countries show that England could still do better in improving CVD mortality rates - as demonstrated by the recent Lancet article on the Global Burden of Disease Study.
Cardiovascular Disease Outcomes Strategy published by Department of Health calls for improving outcomes for people with or at risk of cardiovascular disease by reducing premature mortality rates for CVD by improving prevention, diagnosis and treatment, bringing all services up to the standards of the best. To prevent disease and improve health, it is essential to understand why diseases arise, and conversely why, in many cases, they do not. To do this, it is necessary to study the distribution of natural history of disease in populations and to identify the agents responsible; effective strategies can then be planned. Epidemiology involves the study of populations rather than the direct study of individuals which enhances the practice of medicine by increasing the understanding of how diseases arise and how they might be managed both in the individual and in societies as a whole.
Stroke is one of the top three causes of death in England and a leading cause of adult disability. Approximately 110,000 strokes and a further 20,000 Transient Ischaemic Attacks ('mini strokes') occur in England every year. There are at least 300,000 people in England living with moderate to severe disabilities as a result of stroke. Stroke costs about £7 billion a year.
Most strokes are caused by occlusive arterial disease (obstruction in the vessels providing oxygen rich blood), around 15% are due to atrial fibrillation (AF) which is irregular heart rhythm, and a further 15% or more are associated with carotid stenosis. Many could be avoided if people with AF and Carotid artery stenosis were identified and treated appropriately with antithrombotic, anti-hypertensive and lipid-lowering drugs as well as encouraging them to stop smoking. Some younger patients with tight carotid stenosis, who are well treated medically, can avoid future stroke by appropriate carotid intervention.
The effects of known risk factors can vary enormously from one population to another, and there is still substantial uncertainty as to how important these are in different settings and as to how their importance is changing with time. By understanding the medical, social and ethical factors that affect community health, solutions to public health problems could be developed.
Having access to a large dataset for a range of cardiovascular screening tests provided by Life Line Screening, enable us to reliably study the distribution of natural history of stroke in asymptomatic British and Irish populations and to assess risk factors responsible. We will identify a large cohort of people with asymptomatic Carotid Artery Stenosis (CAS) and AF, drawn from those attending Life Line Screening appointments in the UK to conduct a prospective study to assess the number of cardiovascular events in the cohort and compare it with a group of participants without CAS and AF.
The study consists of an observational, prospective study of the prevalence of and risk factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended cardiovascular screening appointments provided by Life Line Screening. Participants completed a detailed questionnaire and provided information on: prior disease; current medications (i.e. anti-hypertensive, lipid-lowering and anti-platelet therapies); exercise; alcohol intake; smoking history; relevant family medical history; and physical measurements (including height, weight, waist circumference, blood pressure). They were then tested for the following conditions: AF; CAS (with Duplex scanning); Abdominal Aortic Aneurysm (with aortic ultrasound); Peripheral Vascular Disease (with ankle-brachial pressure index). They were provided with a written report and advised to consult their GP to discuss abnormal results. The company recorded all such anonymised data in a research database.
This cohort will have long-term (up to 5 or more years) follow up via an annual interview and/or health questionnaire to determine the contemporary risk of stroke in each group (asymptomatic CAS and/or AF versus no CAS and/or AF).
As the study is quantitative with clear numerical interpretation, Mann-Whitney test and t-test will be used for the statistical analysis. The median and interquartile range will be used to summarise continuous variables such as age. Data and all appropriate documentation will be stored for a minimum of 10 years after the completion of the study.
- Conditions
- Stroke, Heart Attack, TIA, Cardiovascular Diseases
- Keywords
- Stroke, Heart Attack, Asymptomatic Carotid Artery Disease, Atrial Fibrillation
- Medical subject headings
- Stroke, Myocardial Infarction, Cardiovascular Diseases, Atrial Fibrillation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Asymptomatic Carotid Artery Disease, AF | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
The contemporary prevalence of asymptomatic carotid artery disease and atrial fibrillation by age and sex and natural history of stroke associated with asymptomatic carotid lesion and atrial fibrillation identified by screening
Measured: 5 years
Secondary outcomes (1)
Effect of a targeted, comprehensive and cost-effective cardiovascular screening programme on a number of participants with adverse events
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Mar 2014 (estimated)
- Study startFeb 2014
- Primary completionMay 2019
- Study completionMay 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- More trials run by Imperial College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 456 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Collaborators
- University of Oxford, Clinical Trial Service Unit and Epidemiological Studies Unit
- Responsible party
- Sponsor
- Investigators
- Mohssen Chabok, MD, Principal investigator, Imperial College LondonMohammed Aslam, PhD, Study director, Imperial College London
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02077023
- Sponsor's protocol ID
- 13IC0865
- Status last verified
- Jun 2019
- First submitted
- 5 Feb 2014
- Last updated
- 12 Jun 2019
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Observational Study of Natural History of Cardiovascular Diseases
- ClinicalTrials.gov ID
- NCT02077023
- Acronym / sponsor ID
- 13IC0865
- Conditions
- Stroke, Heart Attack, TIA, Cardiovascular Diseases
- Keywords
- Stroke, Heart Attack, Asymptomatic Carotid Artery Disease, Atrial Fibrillation
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 456 participants (actual)
- Lead sponsor
- Imperial College LondonUniversity, hospital or other
- Collaborators
- University of Oxford, Clinical Trial Service Unit and Epidemiological Studies Unit
- Study start
- Feb 2014
- Primary completion
- May 2019 (actual)
- Study completion
- May 2019 (actual)
- First posted
- 4 Mar 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of the study is to estimate the contemporary prevalence of cardiovascular diseases in the United Kingdom (UK) and to describe the incidence and prevalence of stroke, mini stroke (TIA), Heart Attack (MI), deaths and interventions repairs for carotids and occlusive arterial disease in a large population. This study will also allow us to obtain reliable information on the age- and sex-specific relevance of tobacco and alcohol consumption, obesity, diabetes and blood pressure as risk factors for different cardiovascular diseases. By following up a large group of participants for 5 years, we will be able to estimate the annual risk of stroke and other CVD events associated with asymptomatic carotid artery stenosis and atrial fibrillation.
Detailed description
Cardiovascular disease (CVD) affects the lives of millions of people and is one of the largest causes of death and disability in this country. Huge improvements have been made in the prevention and treatment of CVD over the last decade. However, comparisons with other countries show that England could still do better in improving CVD mortality rates - as demonstrated by the recent Lancet article on the Global Burden of Disease Study.
Cardiovascular Disease Outcomes Strategy published by Department of Health calls for improving outcomes for people with or at risk of cardiovascular disease by reducing premature mortality rates for CVD by improving prevention, diagnosis and treatment, bringing all services up to the standards of the best. To prevent disease and improve health, it is essential to understand why diseases arise, and conversely why, in many cases, they do not. To do this, it is necessary to study the distribution of natural history of disease in populations and to identify the agents responsible; effective strategies can then be planned. Epidemiology involves the study of populations rather than the direct study of individuals which enhances the practice of medicine by increasing the understanding of how diseases arise and how they might be managed both in the individual and in societies as a whole.
Stroke is one of the top three causes of death in England and a leading cause of adult disability. Approximately 110,000 strokes and a further 20,000 Transient Ischaemic Attacks ('mini strokes') occur in England every year. There are at least 300,000 people in England living with moderate to severe disabilities as a result of stroke. Stroke costs about £7 billion a year.
Most strokes are caused by occlusive arterial disease (obstruction in the vessels providing oxygen rich blood), around 15% are due to atrial fibrillation (AF) which is irregular heart rhythm, and a further 15% or more are associated with carotid stenosis. Many could be avoided if people with AF and Carotid artery stenosis were identified and treated appropriately with antithrombotic, anti-hypertensive and lipid-lowering drugs as well as encouraging them to stop smoking. Some younger patients with tight carotid stenosis, who are well treated medically, can avoid future stroke by appropriate carotid intervention.
The effects of known risk factors can vary enormously from one population to another, and there is still substantial uncertainty as to how important these are in different settings and as to how their importance is changing with time. By understanding the medical, social and ethical factors that affect community health, solutions to public health problems could be developed.
Having access to a large dataset for a range of cardiovascular screening tests provided by Life Line Screening, enable us to reliably study the distribution of natural history of stroke in asymptomatic British and Irish populations and to assess risk factors responsible. We will identify a large cohort of people with asymptomatic Carotid Artery Stenosis (CAS) and AF, drawn from those attending Life Line Screening appointments in the UK to conduct a prospective study to assess the number of cardiovascular events in the cohort and compare it with a group of participants without CAS and AF.
The study consists of an observational, prospective study of the prevalence of and risk factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended cardiovascular screening appointments provided by Life Line Screening. Participants completed a detailed questionnaire and provided information on: prior disease; current medications (i.e. anti-hypertensive, lipid-lowering and anti-platelet therapies); exercise; alcohol intake; smoking history; relevant family medical history; and physical measurements (including height, weight, waist circumference, blood pressure). They were then tested for the following conditions: AF; CAS (with Duplex scanning); Abdominal Aortic Aneurysm (with aortic ultrasound); Peripheral Vascular Disease (with ankle-brachial pressure index). They were provided with a written report and advised to consult their GP to discuss abnormal results. The company recorded all such anonymised data in a research database.
This cohort will have long-term (up to 5 or more years) follow up via an annual interview and/or health questionnaire to determine the contemporary risk of stroke in each group (asymptomatic CAS and/or AF versus no CAS and/or AF).
As the study is quantitative with clear numerical interpretation, Mann-Whitney test and t-test will be used for the statistical analysis. The median and interquartile range will be used to summarise continuous variables such as age. Data and all appropriate documentation will be stored for a minimum of 10 years after the completion of the study.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Asymptomatic Carotid Artery Disease, AF | – | – |
Who may qualify
- Ages
- 20 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- The study consists of an observational, prospective study of the prevalence of and risk factors for AF, CAS and stroke amongst 5,200 people who voluntarily attended cardiovascular screening appointments provided by Life Line Screening. This cohort will include 1300 participants who are exposed to significant carotid artery stenosis (more than 50% artery occlusion identified by ultrasound scan) and atrial fibrillation. We also aim to recruit 3900 participants who do not have carotid artery disease or atrial fibrillation as control group and for comparison purposes. The control group will be drawn from a population that is similar to the exposed group in all respects other than their carotid disease and atrial fibrillation. The data collected for the control group will be the same and will be obtained in the same way as those on the exposed group.
Key inclusion criteria (5 listed)
- Participants who underwent self-selected, private screening program held by Life Line Screening
- Adult participants over the age of 20
- Participants who filled in appropriate health questionnaire and signed relevant consent part of their questionnaire
- Cohort observation cases: participants with significant carotid artery disease (>50% stenosis) detected by duplex ultrasound and/or AF
- Cohort observation controls: Participants without CAS detected by Duplex ultrasound or AF
Key exclusion criteria (3 listed)
- Those who are unable to give informed consent
- Participants under 20 years old
- Participants who filled in the health questionnaire incompletely
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
The contemporary prevalence of asymptomatic carotid artery disease and atrial fibrillation by age and sex and natural history of stroke associated with asymptomatic carotid lesion and atrial fibrillation identified by screening
Time frame: 5 years
1 secondary outcome
Effect of a targeted, comprehensive and cost-effective cardiovascular screening programme on a number of participants with adverse events
Time frame: 1 year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2019.
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohssen Chabok, MD principal investigator
Imperial College London
Mohammed Aslam, PhD study director
Imperial College London
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Stroke and Heart Attack, run by Imperial College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
The contemporary prevalence of asymptomatic carotid artery disease and atrial fibrillation by age and sex and natural history of stroke associated with asymptomatic carotid lesion and atrial fibrillation identified by screening (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2019.